Pharmacoeconomics and Outcomes Research Iberia-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2024

  1. Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review

    Transplantation Reviews, Vol. 38, Núm. 1

  2. The burden of disease and quality of life in patients with acute hepatic porphyria: COPHASE study

    Medicina Clinica, Vol. 162, Núm. 3, pp. 103-111

2023

  1. Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. 587-605

  2. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

2022

  1. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83

  2. Cribado dirigido del virus de la inmunodeficiencia humana en los servicios de urgencias en España: análisis de las consecuencias epidemiológicas y económicas

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 34, Núm. 1, pp. 21-28

  3. Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain

    PharmacoEconomics - Open, Vol. 6, Núm. 3, pp. 415-424

2017

  1. Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism

    Pharmacoeconomics - Spanish Research Articles, Vol. 14, Núm. 1, pp. 7-18

2016

  1. Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España

    Actas Dermo-Sifiliograficas, Vol. 107, Núm. 6, pp. 498-508

  2. Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and Vitamin K antagonists for treatment and secondary prevention of venous thromboembolism

    Farmacia Hospitalaria, Vol. 40, Núm. 3, pp. 187-208

2015

  1. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain

    International Journal of COPD, Vol. 10, Núm. 1, pp. 2027-2036

  2. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis

    Health Economics Review, Vol. 5, Núm. 1

  3. Cost-effectiveness analysis of lanthanum carbonate versus sevelamer hydrochloride in the treatment of hyperphosphatemia in patients with end-stage renal disease in Spain

    Pharmacoeconomics - Spanish Research Articles, Vol. 12, Núm. 1, pp. 11-22

  4. Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: The CODICE Study

    Neurologia, Vol. 30, Núm. 9, pp. 536-544

2012

  1. Cost effectiveness of prostacyclins in pulmonary arterial hypertension

    Applied Health Economics and Health Policy, Vol. 10, Núm. 3, pp. 175-188

2009

  1. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing crohn's disease

    Journal of Clinical Gastroenterology, Vol. 43, Núm. 10, pp. 950-956